10 Stock Tips From The Street’s Best Analysts

Looking for fresh investing inspiration? We have the perfect tool for you. TipRanks has now revamped its powerful stock screener to enable users to take advantage of our unique and valuable stock insights. 

The upgraded screener includes many exciting new datasets enabling you to refine your search options and find high-quality investing inspiration more easily and efficiently than ever before. New filters include Analyst Price Target and Best Analyst Price Target. The Analyst Price Target specifically is an extremely useful filter that lets you find stocks the Street thinks are set to soar. Using this filter, you can limit the results to only ‘Strong Buy’ stocks with over 10 or 20% upside potential from the current share price to the average analyst price target.

Here we used the following filters: Market Cap Over $300M; All Sectors; Strong Buy Consensus, Upside of Over 10%, Bullish News Sentiment, Bullish Blogger Sentiment 

From the generated results, these 10 stocks stood out. Bear in mind the analyst consensus is based on ratings from the last three months. Let’s take a closer look now:

1. Alphabet (Nasdaq:GOOGL)

  • Strong Buy (29 buy ratings, 3 hold ratings), $1,378 average analyst price target (10% upside potential)

Five-star Monness analyst Brian White has just returned from the Google Cloud conference. This was a ‘Big Day for AI’ says White, as the “new innovations unveiled and capabilities added… will continue to drive momentum in the Google Cloud.” He has a $1,415 price target on the stock (13% upside potential).  

2. Edwards Lifesciences (NYSE:EW)

  • Strong Buy (6 buy ratings, 1 hold rating), $156 average analyst price target (10% upside potential)

Buy EW aggressively here” states top Canaccord Genuity analyst Jason Mills. He has a $177 price target on this medical device stock (25% upside potential). “The reason we are adamant about adding to positions owes to our belief that the firm will deliver accelerating growth in Transcatheter Valve Therapy (TVT) revenue over the next 2 quarters, and quite possibly the next 4 to 6, given myriad catalysts (new products, CAP trial, low risk data and indication expansion through H2:19).”  View EW Price Target & Analyst Rating Details

1 2 3 4
View single page >> |

Disclaimer: TipRanks is an independent cloud based service that measures and ranks digitally published financial advice. TipRanks' natural language processing (NLP) algorithms aggregate and ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.